Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro.

Adrenoleukodystrophy (ALD) and adrenomyeloneuropathy are inherited disorders in which long-chain, saturated fatty acids (LCFA) accumulate in various tissues. A mechanism by which LCFA cause the endocrine and neurological dysfunction characteristic of these diseases is proposed based on in vitro response of human adrenocortical cells to ACTH in the presence of various fatty acids. Human adrenocortical cells cultured in the presence of 5 microM hexacosanoic (C26:0) or lignoceric (C24:0) acids showed decreased basal and ACTH-stimulated cortisol release compared with cells cultured without exogenous fatty acids or in the presence of linoleic acid (C18:2). Measurement of fluorescence polarization demonstrates a significant increase in the membrane microviscosity of cells cultured in the presence of LCFA. It is hypothesized that cells exposed to LCFA have increased membrane microviscosity with a consequent decrease in their ability to respond to ACTH. This decrease in trophic support may contribute to the adrenal insufficiency and atrophy in patients with ALD.

[1]  R. Stouffer,et al.  Modulation of membrane fluidity in the primate (Macaca mulatta) corpus luteum: correlation with changes in gonadotropin binding. , 1985, Endocrinology.

[2]  R. Knazek,et al.  Effects of dietary essential fatty acids on murine mammary gland development. , 1981, Cancer research.

[3]  H. Moser,et al.  The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy. , 1984, The American journal of clinical nutrition.

[4]  M. Schramm,et al.  Fatty acids as modulators of membrane functions: catecholamine-activated adenylate cyclase of the turkey erythrocyte. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Shinitzky,et al.  Microviscosity parameters and protein mobility in biological membranes. , 1976, Biochimica et biophysica acta.

[6]  E. Zackai,et al.  Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. , 1986, American journal of medical genetics.

[7]  T. E. Thompson,et al.  Fluorescence depolarization studies of phase transitions and fluidity in phospholipid bilayers. 2 Two-component phosphatidylcholine liposomes. , 1976, Biochemistry.

[8]  A. Moser,et al.  A new dietary therapy for adrenoleukodystrophy: Biochemical and preliminary clinical results in 36 patients , 1987, Annals of neurology.

[9]  J. Menkes,et al.  Adrenoleukodystrophy: Accumulation of cholesterol esters with very long chain fatty acids , 1977, Neurology.

[10]  Y. Barenholz,et al.  Fluidity parameters of lipid regions determined by fluorescence polarization. , 1978, Biochimica et biophysica acta.

[11]  J. Dave,et al.  Prostaglandin I2 modifies both prolactin binding capacity and fluidity of mouse liver membranes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Moser,et al.  Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. , 1982, The Johns Hopkins medical journal.

[13]  J. Dave,et al.  Modulation of prolactin binding sites in vitro by membrane fluidizers. II. Age-dependent effects on rat ventral prostatic membranes. , 1984, Biochimica et biophysica acta.

[14]  P. Watkins,et al.  Adrenoleukodystrophy , 1986, Neurology.

[15]  H. Moser,et al.  Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy , 1984, Annals of neurology.

[16]  W. Engel,et al.  Abnormalities in cultured muscle and peripheral nerve of a patient with adrenomyeloneuropathy. , 1979, The New England journal of medicine.

[17]  J. Dave,et al.  Arachidonic acid, bradykinin and phospholipase A2 modify both prolactin binding capacity and fluidity of mouse hepatic membranes. , 1981, Biochemical and biophysical research communications.

[18]  H. Moser,et al.  Adrenoleukodystrophy: Impaired Oxidation of Very Long Chain Fatty Acids in White Blood Cells, Cultured Skin Fibroblasts, and Amniocytes , 1984, Pediatric Research.

[19]  G. Radda,et al.  The relation between lipid mobility and the specific hormone binding of thyroid membranes. , 1975, The Biochemical journal.

[20]  J. Dave,et al.  Indomethacin causes a simultaneous decrease of both prolactin binding and fluidity of mouse liver membranes. , 1981, Prostaglandins and medicine.

[21]  K. Suzuki,et al.  FATTY ACID ABNORMALITY IN ADRENOLEUKODYSTROPHY , 1976, Journal of neurochemistry.

[22]  R. Knazek,et al.  Dietary Essential Fatty Acids Are Required for Maintenance and Induction of Prolactin Receptors , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[23]  W. Rizzo,et al.  Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels , 1987, Annals of neurology.

[24]  J. Dave,et al.  Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. , 1983, The Journal of clinical investigation.